title: Management of vascular endothelial growth factor and multikinase inhibitor side effects.
abstract: The availability of vascular endothelial growth factor and multikinase inhibitors (MKIs) has enhanced treatment strategies for patients with advanced kidney cancer. Side effects associated with the agents include dermatologic toxicities, gastrointestinal toxicities, and hematologic and metabolic abnormalities that may interfere with treatment adherence. Nurses play a key role in managing side effects associated with emerging therapies. This article presents a case study to illustrate side-effect management strategies for patients receiving MKIs for the treatment of advanced renal cell carcinoma.
authors: Cleveland Clinic Taussig Cancer Institute, Ohio, USA.
authors: Laura S
authors: LS
authors: Wood
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000451:nursing; D003967:Diarrhea / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D016903:Drug Monitoring; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000009:adverse effects; D007376:Interleukin-2 / Q000009:adverse effects; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000451:nursing; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D009859:Oncology Nursing; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D000077157:Sorafenib; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D007211:Indoles; D007376:Interleukin-2; D047908:Intracellular Signaling Peptides and Proteins; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib